Analyst Research

Report Title Price
Provider: Wright Reports
$75.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: Stock Traders Daily
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Novartis AG Gets European Commission Nod For Kidney Tumor Drug Votubia-Reuters


Monday, 5 Nov 2012 01:23am EST 

Reuters reported that Novartis AG said on November 05, 2012 its drug Votubia had received approval from the European Commission for treating non-cancerous kidney tumors in patients with a rare genetic disease known as tuberous sclerosis complex (TSC). This marks the first approval of a medical treatment in this patient population in Europe. 

Company Quote

76.3
-0.1 -0.13%
10:30am EDT